We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glucagon‐like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta‐analysis of randomised controlled trials.
- Authors
Silverii, Giovanni Antonio; Pala, Laura; Cresci, Barbara; Mannucci, Edoardo
- Abstract
The meta-analysis examined the association between GLP-1 receptor agonists and the risk of ischemic optic neuropathy in patients with obesity and/or type 2 diabetes. While some observational studies suggested a potential link, the meta-analysis of randomized controlled trials did not find a significant detrimental effect of GLP-1 RA therapy on optic neuropathy. The estimated incidence of optic ischemic neuropathy was higher in the GLP-1 RA arm compared to the placebo arm, but the difference was not statistically significant. Further research is needed to fully understand the safety profile of GLP-1 RA, especially in patients at higher risk for optic neuropathy.
- Subjects
GLUCAGON-like peptide-1 receptor; ANTIOBESITY agents; GLUCAGON-like peptide 1; TYPE 2 diabetes; RANDOM effects model; EXENATIDE; SEQUENTIAL analysis; FIXED effects model
- Publication
Diabetes, Obesity & Metabolism, 2025, Vol 27, Issue 2, p1005
- ISSN
1462-8902
- Publication type
Academic Journal
- DOI
10.1111/dom.16076